BBIO CEO sells 223,090 shares under 10b5-1; weighted avg ~$54
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. (BBIO) reported insider sales by Chief Executive Officer and Director Neil Kumar under a Rule 10b5-1 plan. The filing shows multiple market sales on 10/08/2025 and 10/09/2025, totaling 223,090 shares disposed at weighted-average prices in the mid-$54 range. Shares sold were held indirectly through two trusts for which the reporting person is a co-trustee; the report disclaims beneficial ownership except for any pecuniary interest. The transactions were reported on a Form 4 and signed by an attorney-in-fact on 10/10/2025.
Positive
- Sales executed under a Rule 10b5-1 plan, indicating pre-arranged transactions (plan adoption date 03/31/2025).
- Full disclosure on Form 4 with specific sale amounts and weighted-average prices, supporting regulatory transparency.
Negative
- Insider disposed of 223,090 shares, a material block of stock sold across 10/08/2025–10/09/2025.
- Sells reduce indirect trust holdings reported for the CEO (post-transaction indirect balances reported in the filing).
Insights
TL;DR: CEO sold 223,090 shares under a pre-established 10b5-1 plan; sales were from trust holdings.
The sales were executed under a Rule 10b5-1 plan adopted on 03/31/2025, which provides an affirmative defense to insider trading claims when conditions are met. The filing lists weighted-average sale prices in the ranges stated and shows proceeds were generated across 10/08/2025–10/09/2025.
Key dependencies include continued adherence to the plan's terms and that the reporting person disclaims direct beneficial ownership except for any pecuniary interest. Monitor subsequent Form 4 filings for additional plan activity or changes in beneficial ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 20,000 | $54.8023 | $1.10M |
| Sale | Common Stock | 20,000 | $54.8023 | $1.10M |
| Sale | Common Stock | 8,706 | $54.3882 | $474K |
| Sale | Common Stock | 11,294 | $55.0886 | $622K |
| Sale | Common Stock | 8,705 | $54.3883 | $473K |
| Sale | Common Stock | 11,295 | $55.0886 | $622K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $53.82 to $54.81 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Represents the weighted average sale price of the shares sold from $54.82 to $55.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $54.49 to $55.28 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
